FDA con­verts ac­cel­er­at­ed to full ap­proval for Pad­cev-Keytru­da com­bo in blad­der can­cer

The FDA on Fri­day grant­ed full ap­proval to Seagen and Astel­las Phar­ma’s Pad­cev (en­for­tum­ab ve­dotin-ejfv) in com­bo with Mer­ck’s Keytru­da (pem­brolizum­ab) for pa­tients with lo­cal­ly ad­vanced or metasta­t­ic urothe­lial can­cer.

The ap­proval comes a lit­tle less than two months af­ter thou­sands of ES­MO del­e­gates in Oc­to­ber gave a stand­ing ova­tion to con­fir­ma­to­ry tri­al da­ta show­ing the Pad­cev-Keytru­da com­bi­na­tion is the “new stan­dard of care” in first-line blad­der can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER